eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

EXOZ Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

eXoZymes, Inc.NASDAQ: EXOZ

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $214.5K rose 50.9% year over year, ahead of the -63.8% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +50.9% holds above the trailing-twelve-month pace of -63.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$214.5K+200.2% QoQ
Last fiscal yearDec 2025
$114.72K-20.9% YoY
LTMMar 2026
$187.09K-63.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.9%——
1 year-20.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
114.72K USD
Year-over-year change
-20.9%

Accounts Receivables vs competitors

How EXOZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -63.8% is the 3rd highest of 5, against a peer median of -51.2%.
EXOZ Competitors
Accounts Receivables for EXOZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$2.71M USD-128.5%—36.1%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.12M USD+128.6%+72.7%—
TLSATiziana Life Sciences LtdFY2025$692K USD-37.7%+75.9%—
TILInstil Bio, Inc.LTM Mar 2026$608K USD———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$515.9K CAD-64.7%+126.8%—
EXOZeXoZymes, Inc.LTM Mar 2026$187.09K USD-63.8%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$0 USD———
Peer median (excluding EXOZ) —-51.2%+75.9%36.1%

Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.21M)(1.4M)(2.04M)(5.86M)(9.16M)
Depreciation & Amortization59.41K147.75K196.94K267.38K(52.91K)
Deferred Income Tax00000
Stock-Based Compensation198.46K216.5K281.54K1.13M1.99M
Change in Working Capital(536.48K)(190.07K)220.31K(4.02M)380.17K
Accounts Receivables(317.07K)(341.18K)(72.79K)145.04K114.72K
Inventory00000
Accounts Payables(214.43K)118.5K272.89K221.34K311.09K
Other Working Capital(4.99K)32.61K20.21K(4.38M)(45.63K)
Other Non-Cash Items(99K)(35.15K)158.73K(19.4K)341.33K
Operating Cash Flow(1.59M)(1.26M)(1.18M)(8.51M)(6.5M)
Capital Expenditures(422.59K)(185.98K)(288.71K)(396.45K)(169.92K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities110.33K98.77K(22.46K)37.24K19.7K
Investing Cash Flow(312.25K)(87.21K)(311.17K)(359.22K)(150.22K)
Debt Repayment0003.98M(27.71K)
Common Stock Issued2.31M1.36M014.53M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities001M11.82K0
Financing Cash Flow2.31M1.36M1M18.52M(27.71K)
Effect of Forex Changes00000
Net Change in Cash413.45K10.76K(492.04K)9.65M(6.68M)
Free Cash Flow(2.01M)(1.44M)(1.47M)(8.9M)(6.67M)

eXoZymes, Inc.

NASDAQ:EXOZ

Intrinsic Alpha fair value

Locked

Current Price

$5.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.